Vivozon Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Vivozon Pharmaceutical has a total shareholder equity of ₩104.1B and total debt of ₩40.0B, which brings its debt-to-equity ratio to 38.4%. Its total assets and total liabilities are ₩173.6B and ₩69.6B respectively. Vivozon Pharmaceutical's EBIT is ₩4.7B making its interest coverage ratio 1.8. It has cash and short-term investments of ₩17.7B.
Key information
38.4%
Debt to equity ratio
₩40.00b
Debt
Interest coverage ratio | 1.8x |
Cash | ₩17.72b |
Equity | ₩104.07b |
Total liabilities | ₩69.58b |
Total assets | ₩173.65b |
Recent financial health updates
We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Recent updates
We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)
Feb 18Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?
Dec 04Financial Position Analysis
Short Term Liabilities: A082800's short term assets (₩45.1B) do not cover its short term liabilities (₩64.8B).
Long Term Liabilities: A082800's short term assets (₩45.1B) exceed its long term liabilities (₩4.8B).
Debt to Equity History and Analysis
Debt Level: A082800's net debt to equity ratio (21.4%) is considered satisfactory.
Reducing Debt: A082800's debt to equity ratio has increased from 33.9% to 38.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A082800 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A082800 has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 7.7% each year.